Overview

To evaluate the safety and initial efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome.

Eligibility

Inclusion Criteria:

• 18 years old≤Age≤85 years old;
• In 14 days since the onset of respiratory infective symptoms (in 12 days for non-invasive mechanical ventilation patients);
• The nearest PaO2/FiO2≤200mmHg;
• Low peripheral blood lymphocyte count;
• Patients (including patients' partners) did not plan to have children during the trial period and for 4 months after the end of the last dose and agreed to use appropriate and effective contraceptive methods;

Exclusion Criteria:

• Use ECMO before first administration;
• The time between first administration and invasive mechanical ventilation was more than 48h;
• Survival is expected to be no more than 24 hours or a cardiac arrest has occurred 4 weeks before screening;
• Vital organs failure, including the liver, kidneys and heart;
• Immunosuppressed state;
• Serious underlying disease.